The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase

Authors:

Abstract
No abstract available
Funding Information
  • Ministry of Education, Culture, Sports, Science and Technology

This publication has 21 references indexed in Scilit: